AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

21.05.24 18:32 Uhr

Werte in diesem Artikel
Aktien

147,95 EUR 1,20 EUR 0,82%

Indizes

8.237,7 PKT -34,7 PKT -0,42%

4.490,9 PKT -17,5 PKT -0,39%

7.312,4 PKT 12,5 PKT 0,17%

2.903,0 PKT -15,2 PKT -0,52%

2.573,8 PKT 19,6 PKT 0,77%

978,1 PKT 10,7 PKT 1,10%

4.513,3 PKT -31,4 PKT -0,69%

AstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030, which is significantly higher than $43.8 million generated in 2023.By 2030, AstraZeneca plans to launch 20 new medicines, which are also expected to be key contributors to the pipeline. AstraZeneca believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. AstraZeneca will continue investing in disruptive innovation and transformative new technologies and platforms to discover novel medicines.AstraZeneca has been quite successful with its new products and almost every new product it has launched in recent years has done well. AstraZeneca now has 12 blockbuster medicines in its portfolio, with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza, Soliris and Ultomiris. Some new products approved recently are Voydeya (danicopan) to treat extravascular hemolysis in adults with the rare disease paroxysmal nocturnal hemoglobinuria (PNH), Wainua/eplontersen for hereditary transthyretin-mediated amyloidosis, commonly referred to as ATTRv-PN and respiratory syncytial virus (“RSV”) antibody Beyfortus (in partnership with Sanofi [SNY]) to protect newborns and infants.So far this year, the stock has risen 14.5% compared with the industry’s 15.3% rise.Image Source: Zacks Investment Research AstraZeneca said its oncology, biopharmaceuticals and rare disease drugs will be the key drivers of top-line growth. Oncology sales now comprise around 40% of AstraZeneca‘s total revenues. Its blockbuster oncology drugs, such as Tagrisso, Lynparza Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo) are doing consistently well. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.An important oncology candidate in AstraZeneca’s pipeline is datopotamab deruxtecan (Dato-DXd), which is under review in the United States for non-squamous non-small cell lung cancer (NSCLC) and HR+ HER2- breast cancer. Dato-DXd is an antibody drug conjugate or ADC being developed in partnership with Daiichi Sankyo. ADCs are being considered a disruptive innovation in the pharmaceutical industry as it will allow to better treat cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.The July 2021 Alexion acquisition added blockbuster rare disease drugs, C5 inhibitors Soliris and Ultomiris, as well as a growing pipeline of candidates in rare diseases to AstraZeneca’s portfolio. The acquisition diversified AstraZeneca’s portfolio, marking its foray into rare diseases, an increasingly attractive field.AstraZeneca also said it expects to generate a mid-30s percentage core operating margin by 2026 and beyond. In 2023, the core operating margin was 32%.On Tuesday, Sanofi also announced a collaboration with artificial intelligence company OpenAI and Formation Bio to develop AI-powered software that will boost its drug development plans through the use of artificial intelligence.Zacks Rank & Stocks to ConsiderCurrently, AstraZeneca has a Zacks Rank #3 (Hold).AstraZeneca PLC Price and Consensus AstraZeneca PLC price-consensus-chart | AstraZeneca PLC QuoteSome better-ranked stocks from the drug/biotech industry are Ligand Pharmaceuticals LGND and ANI Pharmaceuticals ANIP, both with a Zacks Rank #2 (Buy).In the past 90 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share has increased from $4.42 to $4.56. During the same time frame, the consensus estimate for Ligand’s 2025 earnings per share has increased from $5.11 to $5.27. Year to date, shares of LGND have gained 21.3%.Ligand beat estimates in each of the trailing four quarters, delivering an average surprise of 56.02%.In the past 90 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have risen from $4.12 to $4.44. During the same period, the consensus estimate for ANI Pharmaceuticals’ 2025 earnings per share has risen from $4.80 to $5.04. Year to date, shares of ANIP have climbed 12.0%.ANI Pharmaceuticals beat estimates in each of the last four quarters, delivering an average earnings surprise of 53.90%.Buy 5 Stocks BEFORE Election DayBiden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S. Don’t Wait. Download FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu AstraZeneca PLC

Analysen zu AstraZeneca PLC

DatumRatingAnalyst
18.06.2024AstraZeneca BuyGoldman Sachs Group Inc.
10.06.2024AstraZeneca BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.06.2024AstraZeneca OverweightJP Morgan Chase & Co.
05.06.2024AstraZeneca HoldDeutsche Bank AG
05.06.2024AstraZeneca BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
18.06.2024AstraZeneca BuyGoldman Sachs Group Inc.
10.06.2024AstraZeneca BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.06.2024AstraZeneca OverweightJP Morgan Chase & Co.
05.06.2024AstraZeneca BuyGoldman Sachs Group Inc.
03.06.2024AstraZeneca OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
05.06.2024AstraZeneca HoldDeutsche Bank AG
22.05.2024AstraZeneca HoldDeutsche Bank AG
08.05.2024AstraZeneca HoldJefferies & Company Inc.
30.04.2024AstraZeneca HoldDeutsche Bank AG
26.04.2024AstraZeneca HaltenDZ BANK
DatumRatingAnalyst
04.06.2024AstraZeneca SellUBS AG
21.05.2024AstraZeneca SellUBS AG
15.05.2024AstraZeneca SellUBS AG
26.04.2024AstraZeneca SellUBS AG
25.04.2024AstraZeneca SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"